On behalf of the nation’s radiation oncologists, the American Society for Radiation Oncology expressed strong support for Wednesday’s Senate introduction of bipartisan federal legislation that would rein in restrictive prior authorization practices delaying patient access to critical cancer treatments.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
